David H. Adams, MD, Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring in the United States. Dr. Adams invented the ring, which was recently approved by the Food and Drug Administration.
The tricuspid valve lies between the right atrium and right ventricle of the heart. Tricuspid valve regurgitation occurs when the valve does not close completely and blood leaks back into the right atrium of the heart. If left untreated, tricuspid valve regurgitation can lead to debilitating symptoms including congestive heart failure and irreversible heart damage. Both American and European guidelines for heart valve disease management now emphasize the importance of treating the diseased tricuspid valve at the time of mitral valve surgery.
"Our understanding of the complex 3-dimensional nature of the tricuspid valve in normal and diseased states has progressed over the past several years due to advances in imaging," said Dr. Adams. "We have translated this knowledge into a new concept in tricuspid ring design that combines the characteristics of the currently available tricuspid rings, which up until now have been completely rigid or completely flexible. The Tri-Ad ring has a rigid component to optimally correct the main lesion seen in tricuspid regurgitation, in combination with completely flexible sections to protect delicate tissue while the valve and heart changes its 3-dimensional shapes throughout the cardiac cycle."
Until recently, "surgical abstention" has been the norm in dealing with functional tricuspid regurgitation, with the assumption that tricuspid regurgitation should resolve once the primary cause—typically mitral stenosis or regurgitation—is eliminated. Annuloplasty rings are specially designed to help restore the tricuspid valve to its normal size and shape—the valve is often enlarged or distorted in a diseased state.
"We also increased the open side of the new ring to better accommodate the heart's conduction system, which is intimately associated with the tricuspid valve. So in addition to a more advanced physiologic repair concept, the Tri-Ad ring design will also protect against damage to the electrical system of the heart," said Dr. Adams.
For pictures of the first implantation and more information, visit http://www.mitralvalverepair.org/triad.
Dr. Adams is a named inventor and receives royalties on heart valve repair rings with Medtronic and Edwards Lifesciences. Dr. Adams is also National Co-Principal Investigator of the upcoming FDA Medtronic-CoreValve Pivotal Trial.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2009, U.S. News & World Report ranked The Mount Sinai Hospital among the nation's top 20 hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
For more information, visit www.mountsinai.org. Follow us on Twitter @mountsinainyc.